Introduction {#sec1}
============

Cardiovascular disease (CVD) is a major cause of death all over the world \[[@cit0001], [@cit0002]\]. Atherosclerosis is a chronic inflammatory disease in the vascular walls \[[@cit0003], [@cit0004]\] that is initiated and progresses via an interplay among multiple factors including proinflammatory cytokines and acute phase proteins such as C-reactive protein (CRP) and fibrinogen \[[@cit0005]\]. Coronary artery atherosclerosis is a key risk factor in the development of acute coronary syndrome \[[@cit0006]\].

Among various established clinical and laboratory risk factors associated with the pathogenesis of CVD (e.g. diabetes, hypertension, hyperlipidemia, dyslipidemia and smoking), several lines of evidence have shown that bacterial pathogens may play a main role \[[@cit0001], [@cit0004], [@cit0007], [@cit0008]\]. Bacterial infections can contribute to CVD mainly through interaction with inflammatory and immunological pathways, either directly or indirectly \[[@cit0001]\]. Infection has been found to directly impair endothelial function by circulating endotoxins, induce proliferation of smooth muscle cells and local inflammation, and activate the innate immune response \[[@cit0009]\]. On the other hand, indirect damaging effects of bacterial infections include induction of proinflammatory, hypercoagulability and atherogenic responses, oxidation of low-density lipoprotein, antigen mimicry between bacterial and host cells, induction of nutrient/vitamin malabsorption, and metabolic disruptions such as excess production of ammonia. To sum up, repeated exposure to bacterial infections leads to an excess inflammatory process leading to the provocation of immune responses that adversely affect cardiovascular risk factors such as triglycerides, high-density lipoprotein, C-reactive protein, heat shock proteins, cytokines, fibrinogen, and white blood cell count. Different bacterial species related to the risk of CVD include *Helicobacter pylori*, *Chlamydia pneumonia*, *Mycoplasma pneumonia* and *Porphyromonas gingivalis* \[[@cit0007]--[@cit0011]\].

In Iran, a developing country in the Middle East, atherosclerosis is a prevalent disease with a high morbidity and mortality burden \[[@cit0007]\]. The association between CVD and bacterial infections is not fully known in the Iranian population and some studies have emphasized the existence of a relationship, while others have not found any association. Therefore, we aimed to investigate the possible relationship between main bacterial infections and CVD among Iranian patients using a systematic review and meta-analysis approach.

MATERIAL AND METHODS {#sec2}
====================

Search strategy {#sec2.1}
---------------

Up to June 30, 2017, a comprehensive search of publications was performed on the relationship between bacterial infections and CVD in Iran using both Persian- and English-language databases including Scientific Information Database ([www.sid.ir](http://www.sid.ir)), Irandoc ([www.irandoc.ac.ir](http://www.irandoc.ac.ir)), Iranmedex ([www.iranmedex.ir](http://www.iranmedex.ir)) and Magiran ([www.magiran.com](http://www.magiran.com)) as well as PubMed, MEDLINE, Scopus, Google Scholar and ISI web of knowledge. The following search terms were selected from the MeSH database: "heart diseases" OR "cardiovascular diseases" OR "coronary artery disease" OR "atherosclerosis" OR "myocardial infarction" OR "ischemic heart disease" AND "bacterial infections" OR "*H. pylori*" OR "*C. pneumonia*" OR "*P. gingivalis*" OR "*M. pneumonia*" OR "bacterial periodontal diseases" AND "Iran". Additional related articles were obtained through scanning the reference lists and hand searching. Drafting the systematic reviews and meta-analysis was based on the PRISMA checklist \[[@cit0012]\].

Study eligibility criteria {#sec2.2}
--------------------------

After evaluating article titles, abstracts and keywords, case-control studies were selected based on the eligibility criteria including: 1) case-control studies published in Persian and English languages, 2) assessing the relationship between bacterial infections and CVD in Iran, and 3) reporting the prevalence of CVD only in humans. Exclusion criteria were: 1) studies published in other languages, 2) articles except cross-sectional or case-control studies, 3) cross-sectional studies without a control comparator, 4) papers without full text, 5) Persian articles without an English abstract, 6) review articles, 7) duplicate studies, for which only the most recent reports were included, 8) studies presented in conferences as abstracts, 9) assessment of relationships between viral, fungal and parasitic infections with CVD, and 10) evaluated the prevalence rate of bacterial infection and CVD alone.

Data collection process {#sec2.3}
-----------------------

To reduce possible bias and mistakes, data extraction from each included study was performed by independent authors. Two reviewers extracted data after reviewing the title, abstract and full text of papers and the following information was then extracted and summarized in [Table I](#t0001){ref-type="table"} \[[@cit0013]--[@cit0031]\]: 1) first author's surname, 2) year of the study, 3) area (city) of the study, 4) mean age for case and control groups, 5) gender (F/M) ratio for case and control groups, 6) number of patients with different types of CVD, 7) CVD type, 8) type and number of bacterial infections, and 9) bacterial infection detection techniques.

###### 

Profile of selected studies in the meta-analysis

  Author \[ref.\]                          Year         Area          Age \[years\]   Gender (F/M)   Case group (*n*)   Control group (*n*)   Disease type   Type and number of bacterial infections (*n*)   Infection detection method                                                                                                                                               
  ---------------------------------------- ------------ ------------- --------------- -------------- ------------------ --------------------- -------------- ----------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- --------------------------
  Khodaii *et al.* \[[@cit0013]\]          2010         Tehran        53.1            48.5           240/260            250/250               500            500                                             Acute myocardial infarction                             *H. pylori* IgG (330)                                    *H. pylori* (100)                                       Serologic test (IgG)
  Dabiri *et al.* \[[@cit0014]\]           2006--2007   Tehran        59              45             11/22              9/22                  33             31                                              Atherosclerosis                                         *C. pneumonia* PCR (6) DIF (7)                           *C. pneumonia* 0                                        PCR DIF
  Nozari *et al.* \[[@cit0015]\]           2006--2007   Tehran        62              61             27/43              29/31                 70             60                                              Atherosclerosis                                         *H. pylori* (56)                                         *H. pylori* (39)                                        Serologic test (IgG)
  Davoudi *et al.*\[[@cit0016]\]           2006--2007   Tehran        60.5            57.57          16/53              39/45                 69             84                                              Atherosclerosis                                         *H. pylori* (40)                                         *H. pylori* (48)                                        Serologic test (IgG)
  Bahrmand *et al.* \[[@cit0017]\]         2001         Tehran        NA              NA             20/34              NA                    54             24                                              Atherosclerosis                                         *C. pneumonia* PCR (14) IgA (10) IgG (39)                *C. pneumonia* 0                                        PCR MIF
  Rogha *et al.* \[[@cit0018]\]            2010--2011   Isfahan       62.4            59.05          20/42              17/26                 62             43                                              Atherosclerosis                                         *H. pylori* (30)                                         *H. pylori* (16)                                        Serologic test (IgG)
  Ashtari *et al.* \[[@cit0019]\]          2005--2006   Isfahan       68.71           66.01          19/23              48/34                 42             82                                              Atherosclerosis                                         *C. pneumonia* IgA (7) IgG (11)                          *C. pneumonia* IgA (5) IgG (15)                         Serologic test (IgA IgG)
  Sarraf-Zadegan *et al.* \[[@cit0007]\]   1998--1999   Isfahan       55              50.8           15/37              15/40                 52             55                                              Acute myocardial infarction                             *H. pylori* (36)                                         *H. pylori* (8)                                         Serologic test (IgG)
  Sadeghian *et al.* \[[@cit0020]\]        2010         Mashhad       32              NA             5/25               NA                    30             30                                              Atherosclerosis                                         *C. pneumonia* (1)                                       *C. pneumonia* 0                                        PCR
  Assar *et al.* \[[@cit0021]\]            2010--2011   Bandarabbas   61              62.35          43/42              44/41                 85             85                                              Atherosclerosis                                         *C. pneumonia* (25)                                      *C. pneumonia* (5)                                      PCR
  Vafaeimanesh *et al.* \[[@cit0022]\]     2013         Qom           57.9            53.1           27/35              32/26                 62             58                                              Atherosclerosis                                         *H. pylori* (46)                                         *H. pylori* (30)                                        Serologic test (IgG)
  Azarkar *et al.* \[[@cit0023]\]          2011         Birjand       59.8            56.4           20/53              29/49                 73             78                                              Acute myocardial infarction                             *H. pylori* IgA (31) IgG (42)                            *H. pylori* IgA (38) IgG (25)                           Serologic test (IgA IgG)
  Jafarzadeh *et al.* \[[@cit0024]\]       2007--2008   Rafsanjan     55.2            52.9           46/74              27/33                 120            60                                              Acute myocardial infarction and unstable angina         *H. pylori* (107)                                        *H. pylori* (35)                                        Serologic test (IgG)
  Karimi *et al.* \[[@cit0025]\]           2003--2004   Rafsanjan     52              52             22/36              11/18                 58             29                                              Acute myocardial infarction and chronic stable angina   *C. pneumonia* (48)                                      *C. pneumonia* (9)                                      Serologic test (IgG)
  Nejad *et al.* \[[@cit0006]\]            2013         Qazvin        58.57           57.98          33/57              29/61                 90             90                                              Acute myocardial infarction                             *H. pylori* (IgA: 48 IgG: 84) *M. pneumonia* (IgG: 69)   *H. pylori* (IgA: 61 IgG:76) *M. pneumonia* (IgG: 63)   Serologic test (IgA IgG)
  Iranpour *et al.* \[[@cit0026]\]         2014         Bushehr       65.3            61.6           19/71              49/41                 90             90                                              Atherosclerosis                                         *C. pneumonia* (9)                                       *C. pneumonia* (6)                                      Serologic test (IgM IgG)
  Zibaeenezhad *et al.* \[[@cit0027]\]     2002         Shiraz        57.4            50             41/68              40/18                 109            58                                              Atherosclerosis                                         *C. pneumonia* (93)                                      *C. pneumonia* (43)                                     Serologic test (IgA IgG)
  Pourahmad *et al.* \[[@cit0028]\]        2005--2007   Jahrom        62.29           61.71          14/31              21/24                 45             45                                              Acute myocardial infarction                             *M. pneumonia* (21)                                      *M. pneumonia* (11)                                     Serologic test (IgG)
  Alavi *et al.* \[[@cit0029]\]            2004--2005   Ahwaz         56.48           58.03          53/43              50/46                 96             96                                              Unstable angina                                         *H. pylori* (79)                                         *H. pylori* (55)                                        Serologic test (IgG)
  Ansari *et al.* \[[@cit0030]\]           2010         Tabriz        55              26             91/9               77/12                 100            89                                              Atherosclerosis                                         *H. pylori* (68)                                         *H. pylori* (44)                                        Serologic test (IgG)

PCR -- polymerase chain reaction, DIF -- immunofluorescence assay, MIF -- micro-immunofluorescence, NA -- not available.

Data synthesis {#sec2.4}
--------------

Comprehensive Meta-Analysis (CMA) software version 2.2 (Biostat, Englewood, NJ, USA) was used for statistical analysis and the association between bacterial infections and CVD was expressed as odds ratio (OR) and 95% confidence interval (95% CI). Risk of publication bias was evaluated using Begg's and Egger's tests. Existence of heterogeneity across studies was determined using the Cochrane Q test and the inconsistency index (*I*^2^). In the case of small and large heterogeneity, fixed- and random-effects models were used to pool the results. In all analyses, *p* \< 0.05 was considered as statistically significant.

RESULTS {#sec3}
=======

Study characteristics {#sec3.1}
---------------------

As shown in the flow diagram, a total of 20 case-control studies were obtained on the relationship between different bacterial infections and CVD in Iran up to June 30, 2017. Briefly, 1807 original articles were collected from various national and international databases. After title, abstract and full text screening, 1792 articles were omitted based on exclusion criteria. Five articles were included after assessing the references and the meta-analysis was performed on 20 selected articles. Several papers were excluded because they had no effect on meta-analysis results. These selected papers were from Tehran (5 studies), Isfahan (3 studies), Rafsanjan (2 studies), and Mashhad, Tabriz, Shiraz, Ahwaz, Qazvin, Qom, Bandar Abbas, Bushehr, Birjand, and Jahrom (each with 1 study) ([Figure 1](#f0001){ref-type="fig"}). Profiles of selected studies in the meta-analysis are listed in [Table I](#t0001){ref-type="table"} \[[@cit0013]--[@cit0030]\]. Serological tests were the most important techniques used for the diagnosis of bacterial infections in patients with CVD in Iran. The most common type of CVD was atherosclerotic CVD.

![Flow diagram of select studies](AMS-15-36791-g001){#f0001}

The association between *C. pneumonia* infection and CVD {#sec3.2}
--------------------------------------------------------

In Iran, a total of 8 relevant studies evaluated the association between *C. pneumonia* infection and CVD ([Table I](#t0001){ref-type="table"}). Molecular and serological methods were the most important diagnostic tests for the detection of *C. pneumonia* infection. Based on PCR, IgG and IgA tests, *C. pneumonia* infection prevalence in case groups was 22.7% (46/202), 56.6% (200/353), and 53.6% (110/205), respectively. However, in control groups, the positive rate of *C. pneumonia* infection on the basis of PCR, IgG and IgA tests was 2.9% (5/172), 25.7% (73/283), and 29.2% (48/164), respectively. Odds ratios for the association between *C. pneumonia* infection and CVD based on PCR, IgG and IgA tests were 7.420 (95% CI: 3.088--17.827), 3.710 (95% CI: 1.361--10.115) and 2.492 (95% CI: 1.305--4.756), respectively ([Figure 2](#f0002){ref-type="fig"}).

![Forest plot of *C. pneumonia* infection associated with heart disease risk in Iran. **A** -- PCR, **B** -- IgG, **C** -- IgA-based tests](AMS-15-36791-g002){#f0002}

There was low heterogeneity of the included studies; therefore, we used a fixed-effect model for assessing the association between *C. pneumonia* infection and CVD on the basis of PCR (*p* = 0.829, *I*^2^ = 0%) and IgA (*p* = 0.480, *I*^2^ = 0%). However, based on the IgG test (*p* = 0.002, *I*^2^ = 75.7%), a random-effects model was used to demonstrate the association between infection and disease. As shown in [Table II](#t0002){ref-type="table"}, Begg's and Egger's tests were used to evaluate publication bias of studies.

###### 

Publication bias results based on Begg's and Egger's tests

  Tests                           Number of studies   Begg's test   Egger's test                                              
  ------------------------------- ------------------- ------------- -------------- --------- ------- --------- --------- ---- -------
  PCR-based *C. pneumonia* test   4                   2             0.16667        0.33968   0.734   0.63170   0.52260   2    0.653
  IgG-based *C. pneumonia* test   5                   2             0.10000        0.24495   0.806   2.28331   1.78504   3    0.172
  IgA-based *C. pneumonia* test   3                   3             0.66667        1.04447   0.296   0.11795   14.1306   1    0.044
  IgG-based *M. pneumonia* test   2                   --            --             --        --      --        --        --   --
  IgG-based *H. pylori* test      11                  1             0.0            0.0       1.000   1.62965   2.09613   9    0.065
  IgA-based *H. pylori* test      2                   --            --             --        --      --        --        --   --

The association between *M. pneumonia* infection and CVD {#sec3.3}
--------------------------------------------------------

There were only 2 studies evaluating the association between *M. pneumonia* infections and CVD in Iran. IgG-based serologic testing was the only method used to detect *M. pneumonia* infection ([Table I](#t0001){ref-type="table"}). In the present study, the prevalence rate of *M. pneumonia* infection on the basis of the IgG test in case and control groups was 66.6% (90/135) and 54.8% (74/135), respectively. Moreover, the calculated odds ratio for *M. pneumonia* infection was 1.815 (95% CI: 0.973--3.386).

A fixed-effect model was applied, due to low heterogeneity (*p* = 0.252, *I*^2^ = 23.7%), to pool results and to evaluate the association between *M. pneumonia* infection and CVD on the basis of IgG ([Figure 3](#f0003){ref-type="fig"}).

![Forest plot of *M. pneumonia* infection associated with heart disease risk in Iran (IgG-based test)](AMS-15-36791-g003){#f0003}

The association between *H. pylori* infection and CVD {#sec3.4}
-----------------------------------------------------

As shown in [Table I](#t0001){ref-type="table"}, using serologic tests, the association between *H. pylori* infection and CVD was assessed in 10 articles in Iran. Based on IgG, the prevalence of *H. pylori* infection among case and control groups was 70.9% (918/1294) and 39.2% (476/1213), respectively. Furthermore, the calculated odds ratio was 3.160 (95% CI: 1.957--5.102) ([Figure 4 A](#f0004){ref-type="fig"}). Based on IgA, the prevalence of *H. pylori* infection was 48.4% (79/163) for case groups and 58.9% (99/168) for control groups. The calculated odds ratio for *H. pylori* infection was 0.643 (95% CI: 0.414--0.999) ([Figure 4 B](#f0004){ref-type="fig"}).

![Forest plot of *H. pylori* infections associated with heart disease risk in Iran. **A** -- IgG, **B** -- IgA-based tests](AMS-15-36791-g004){#f0004}

Finally, to pool the results of the IgG-based *H. pylori* test (*p* \< 0.001, *I*^2^ = 83%), a random-effects model was used, and for the IgA-based H. *pylori* test (*p* = 0.427, *I*^2^ = 0%), a fixed-effect model was used.

Discussion {#sec4}
==========

The risk factors for the emergence and development of CVD are not the same in different patients \[[@cit0015]\]. More than a century ago, potential roles of infectious organisms including bacteria and viruses as potent risk factors in the induction of heart diseases were investigated in several epidemiological studies \[[@cit0031]\]. *Chlamydia pneumonia*, a Gram-negative and obligate intracellular bacterium, was the first proposed etiologic agent responsible for the induction of inflammation in the vessel walls of patients with CVD \[[@cit0031], [@cit0032]\]. In Iran, the prevalence of *C. pneumonia* infection in patients with CVD is rather high \[[@cit0014]\]. However, there are confusing results about the role of *C. pneumonia* in the pathogenesis of the disease in Iran and the world. For example, Sadeghian *et al*. \[[@cit0020]\], Zibaeenezhad *et al*. \[[@cit0027]\], West *et al*. \[[@cit0033]\] and Apfalter *et al*. \[[@cit0034]\] did not find a link between *C. pneumonia* infection and CVD, while Dabiri *et al*. \[[@cit0014]\], and Sessa *et al*. \[[@cit0035]\] found a significant correlation. These differences in results may be due to the variations in sampling, population size, applied detection technique, ethnicity, region, and disease type \[[@cit0021]\]. In the present study, the prevalence of *C. pneumonia* infection was higher in case groups compared with control groups, as detected by PCR, IgG and IgA tests ([Figures 2 A--C](#f0002){ref-type="fig"}). In addition, our findings showed that the detection rate of *C. pneumonia* using molecular methods was lower than the serological methods in both case (22.7% vs. 56.6% and 53.6%) and control groups (2.9% vs. 25.7% and 29.2%). Based on the molecular detection methods, the prevalence of *C. pneumonia* among Iranian subjects with CVD (22.7%) was higher than in India (10%) \[[@cit0036]\] and Turkey (15%) \[[@cit0037]\], and lower than in Poland (27%) \[[@cit0038]\] and Japan (62%) \[[@cit0039]\]. Our results support the notion that there is a significant association between *C. pneumonia* and CVD risk in the Iranian people.

*Helicobater pylori*, a Gram-negative and microaerophilic bacterium, colonizes the stomach of approximately 50% of the world's population and is involved in gastritis, peptic ulcer, adenocarcinoma and MALT lymphoma \[[@cit0040]--[@cit0042]\]. There is inconsistent evidence on the association between *H. pylori* infection and CVD risk in Iran. Khodaii *et al*. \[[@cit0013]\] reported a significant association between *H. pylori* infection and CVD. In contrast, no association was found between *H. pylori* infection and CVD in a study reported by Eskandarian *et al*. \[[@cit0043]\]. In the present meta-analysis, we found a significant correlation between *H. pylori* infection and CVD risk in Iran based on the IgG test (OR = 3.160, *p* \< 0.001). However, there was no relationship between *H. pylori* infection and CVD based on the IgA test (OR = 0.643, *p* = 0.049). One reason for this inconsistency could be the low number of studies in the latter category (*n* = 2). Two studies from Poland and Germany showed a significant association between *H. pylori* infection (detected according to genotypic and serological methods, respectively) and CVD risk \[[@cit0038], [@cit0044]\]. In contrast, one study from Austria did not suggest a main role for *H. pylori* infection in CVD \[[@cit0045]\]. The existence of these conflicting results suggests that the use of highly sensitive and specific methods is necessary to confirm the hypothetical relationship between infectious agents and the development of CVD.

In recent studies, it was suggested that the smallest pathogenic cause of atypical pneumonia in human is *M. pneumonia*, which is a common respiratory tract microorganism related to CVD risk either alone or along with other risk factors \[[@cit0046]\]. However, in Iran, only 2 studies assessed this possible risk using serological tests ([Table I](#t0001){ref-type="table"}). In the present study, the obtained odds ratio for *M. pneumonia* infection among case groups with CVD was 1.815. It suggests that *M. pneumonia* infection may be a risk factor for CVD. Similar finding were reported in Saudi Arabia \[[@cit0046]\], Japan \[[@cit0047]\], the Netherlands \[[@cit0048]\] and Germany \[[@cit0044]\]. Inconsistently with our results, the role of *M. pneumonia* infection in the etiopathogenesis of CVD has been refuted in some studies \[[@cit0038], [@cit0045]\]. Various sensitivity and specificity values for different diagnostic tests for detecting *M. pneumonia* infection in patients with CVD may be an important reason for discrepancies in the results obtained in different studies \[[@cit0048]\]. In this meta-analysis, no study was found on the association between *P. gingivalis* infection and resulting bacterial periodontal infections and CVD risk in Iran. Finally, we recommend evaluation of the association between cardiovascular risk factors and biomarkers such as plasma low- and high-density lipoprotein (LDL and HDL) and vitamin D status with various bacterial infections that predispose to CVD \[[@cit0049]--[@cit0051]\].

In conclusion, the present systematic review focused on the association between different bacterial infections and CVD risk in Iran. Our meta-analysis revealed that *H. pylori*, *C. pneumonia* and *M. pneumonia* infections could be considered as potential risk factors for CVD in Iran. These findings are worthwhile to confirm the role of bacterial infections as predisposing factors for CVD and also explore the bacterial species that have a stronger association with CVD. Based on the present findings, efficient and timely eradication of *H. pylori*, *C. pneumonia* and *M. pneumonia* infections could be a useful strategy to reduce the burden of CVD. This study was limited in several ways including heterogeneity of diagnostic tests used for the detection of infections, and lack of a complete spectrum of studied bacterial species in relation to CVD. Furthermore, our analysis was limited to Iran, and a global investigation will be crucial for generalization of the findings. Based on the mentioned limitations, additional studies are needed to explain the difference between obtained results on the basis of various bacterial infection detection methods. Finally, the association between other bacterial infections and CVD risk in Iran merits further investigations.
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